Clobetasol Suspension Eases Cataract Inflammation
Phase 3 trials show clobetasol propionate ophthalmic suspension rapidly reduced inflammation and pain after cataract surgery
Objective:
To evaluate the efficacy and safety of clobetasol propionate ophthalmic suspension 0.05% for controlling inflammation and pain after cataract surgery.
Approach:
- Study Design: Pooled analysis of two multicenter, randomized, double-masked Phase 3 trials involving 748 patients.
- Treatment Protocol: Patients received clobetasol propionate 0.05% or placebo twice daily for 14 days starting on postoperative day one.
Key Findings:
- 26.5% of clobetasol-treated patients achieved complete anterior chamber cell clearance by day eight compared to 6.8% in the placebo group.
- 71.6% of patients treated with clobetasol reported complete absence of ocular pain by day four, versus 27.7% in the placebo group.
- Pain-free rates exceeded 80% by postoperative day four, and visual acuity recovery was faster in the clobetasol group.
Interpretation:
Limitations:
- Absence of an active steroid comparator.
- Exclusion of patients with glaucoma or histories of steroid-related IOP elevation.
Conclusion:
Sources:
